Neuronal injury after photoactivation of photofrin II.
Photodynamic therapy has been used in the management of patients with malignant brain tumors even though the effects of this form of treatment on the adjacent normal brain are incompletely characterized. The authors examined, in sequential experiments, morphologic alterations affecting the cerebral cortex in rats injected with Photophrin II and exposed to light. Initially, minimal cell alterations, including cisternal swelling of both endoplasmic reticulum and Golgi apparatus, involved only neurons located in the superficial layers of the cerebral cortex exposed to light. These changes spread, over a period of several hours, from the surface to the bottom of the cortex and eventually involved the entire cortical segment exposed to light. The earliest structural signs of lethal injury to neurons developed over a period of 18 hours after porphyrins had been photoactivated and astrocytes had been severely damaged. Signs of lethal injury to neurons included an increase in the number of mitochondrial cristae and appearance of amorphous electron-dense deposits within swollen mitochondria. The appearance of these alterations was followed by segregation of intracytoplasmic organelles and fragmentation of nuclear and cytoplasmic membranes. The tissue changes, including those involving neurons, eventually progressed to coagulation necrosis at 48 hours. These observations suggest that prophyrins injected to rats (48 hours before photoactivation) cause swelling and necrosis of astrocytes. This is followed by neuronal necrosis, which appears at two time intervals; the initial neuronal necrosis occurs after the astrocytic disintegration. A second type of neuronal alteration appears after microvessels become thrombosed and ischemia is likely to develop.
Yoshida
Y
Y
Department of Pathology, Henry Ford Hospital, Detroit, Michigan 48202-2689.
Dereski
M O
MO
Garcia
J H
JH
Hetzel
F W
FW
Chopp
M
M
D000818:Animals; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects*; D017323:Dihematoporphyrin Ether / Q000009:adverse effects*; D008297:Male; D009336:Necrosis; D009474:Neurons / Q000187:drug effects* / Q000648:ultrastructure; D010778:Photochemotherapy / Q000009:adverse effects*; D051381:Rats
D017323:Dihematoporphyrin Ether